Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer
NCT04808687Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and tegafur in pancreatic cancer (PC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
paclitaxeltegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04808687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808687.